Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00863655 · OUTCOME

Overall Survival (OS) by Median

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole · Source last updated 2017-05-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
up to 53 months

What was measured

Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause.

Analysis population: All randomized patients were included in the Full Analysis Set.

Groups in this outcome

Everolimus + Exemestane

Everolimus 10 mg daily in combination with exemestane 25 mg daily

Placebo + Exemestane

Placebo of everolimus in combination with exemestane 25 mg daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Everolimus + Exemestane485
Placebo + Exemestane239

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Everolimus + Exemestane30.98Not reported27.9634.56Not reported
Placebo + Exemestane26.55Not reported22.5733.08Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        27.96
        upper Limit
        34.56
        value
        30.98
      2. group Id
        OG001
        lower Limit
        22.57
        upper Limit
        33.08
        value
        26.55
denoms
  1. counts
    1. group Id
      OG000
      value
      485
    2. group Id
      OG001
      value
      239
    units
    Participants
description
Overall survival, the key secondary endpoint in this study, is defined as the time from date of randomization to the date of death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Everolimus 10 mg daily in combination with exemestane 25 mg daily
    id
    OG000
    title
    Everolimus + Exemestane
  2. description
    Placebo of everolimus in combination with exemestane 25 mg daily
    id
    OG001
    title
    Placebo + Exemestane
param Type
MEDIAN
population Description
All randomized patients were included in the Full Analysis Set.
reporting Status
POSTED
time Frame
up to 53 months
title
Overall Survival (OS) by Median
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice